5-aminotetrahydroquinoline-2-carboxylic acids and their use

Patent metadata

Field	Value
Publication number	US-9688636-B2
Application number	US-201514609122-A
Country	US
Kind code	B2
Filing date	Jan 29, 2015
Priority date	Jul 20, 2012
Publication date	Jun 27, 2017
Grant date	Jun 27, 2017

Abstract

The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.

First claim

The invention claimed is:

1. A compound having the formula:

2. A compound having the formula:

or a salt, solvate, or solvate of the salt thereof.

3. A pharmaceutical composition comprising the compound of claim 1 and at least one inert non-toxic pharmaceutically acceptable auxiliary.

4. The pharmaceutical composition of claim 3 , further comprising at least one active compound selected from the group consisting of an organic nitrate, a NO donor, a PDE 5 inhibitor, a prostacyclin analogue, an IP receptor agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, a tyrosine kinase inhibitor, an anti-obstructive agent, an anti-inflammatory and/or immunosuppressive agent, an antithrombotic agent, an agent for lowering blood pressure, and an agent that alters fat metabolism.

5. A method for the treatment of primary and secondary forms of pulmonary hypertension and hypertension, comprising administering an effective amount of the compound of claim 1 to a human or animal in need thereof.

6. A pharmaceutical composition comprising the compound of claim 2 and at least one inert non-toxic pharmaceutically acceptable auxiliary.

7. The pharmaceutical composition of claim 6 , further comprising at least one active compound selected from the group consisting of an organic nitrate, a NO donor, a PDE 5 inhibitor, a prostacyclin analogue, an IP receptor agonist, an endothelin receptor antagonist, a guanylate cyclase stimulator, a tyrosine kinase inhibitor, an anti-obstructive agent, an anti-inflammatory and/or immunosuppressive agent, an antithrombotic agent, an agent for lowering blood pressure, and an agent that alters fat metabolism.

8. A method for the treatment of primary and secondary forms of pulmonary hypertension and hypertension comprising administering an effective amount of the compound of claim 2 to a human or animal in need thereof.

Assignees

• Bayer Pharma AG

Inventors

• Hahn Michael
• Follmann Markus
• Hübsch Walter
• Becker Eva-Maria
• Stasch Johannes-Peter
• Keldenich Joerg
• Delbeck Martina
• Tinel Hanna
• Wunder Frank
• Mittendorf Joachim
• Terebesi Ildiko
• Lang Dieter
• Martin René

Classifications

• A61P9/12

  Antihypertensives · CPC title

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P9/04

  Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure · CPC title